(NASDAQ: RVMD) Revolution Medicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.43%.
Revolution Medicines's earnings in 2026 is -$1,371,701,000.On average, 26 Wall Street analysts forecast RVMD's earnings for 2026 to be -$1,730,110,008, with the lowest RVMD earnings forecast at -$1,862,600,123, and the highest RVMD earnings forecast at -$1,607,229,253. On average, 25 Wall Street analysts forecast RVMD's earnings for 2027 to be -$1,244,709,766, with the lowest RVMD earnings forecast at -$2,237,620,282, and the highest RVMD earnings forecast at $214,297,234.
In 2028, RVMD is forecast to generate -$494,180,476 in earnings, with the lowest earnings forecast at -$1,447,994,503 and the highest earnings forecast at $1,319,267,345.